Article Details

NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with ...

Retrieved on: 2023-12-29 20:39:05

Tags for this article:

Click the tags to see associated articles and topics

NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with .... View article details on hiswai:

Excerpt

SANTA ANA, CA, USA I December 28, 2023 I NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up